| Title |
Ocrelizumab: First Global Approval
|
|---|---|
| Published in |
Drugs, May 2017
|
| DOI | 10.1007/s40265-017-0757-6 |
| Pubmed ID | |
| Authors |
James E. Frampton |
| Abstract |
Ocrelizumab (Ocrevus™) is a humanised anti-CD20 monoclonal antibody that has been developed by Genentech, Inc. (a subsidiary of Roche) for the treatment of multiple sclerosis (MS). The drug is designed to deplete B cells, which play an important role in the pathogenesis of MS. In March 2017, ocrelizumab was approved in the USA for the treatment of patients with relapsing or primary progressive forms of MS; currently, it is awaiting approval in the EU for the same indications. This article summarizes the milestones in the development of ocrelizumab leading to its first global approval for the treatment of MS. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 57 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 9 | 16% |
| Student > Master | 7 | 12% |
| Researcher | 6 | 11% |
| Student > Postgraduate | 4 | 7% |
| Student > Ph. D. Student | 4 | 7% |
| Other | 8 | 14% |
| Unknown | 19 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 32% |
| Neuroscience | 6 | 11% |
| Biochemistry, Genetics and Molecular Biology | 5 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 5 | 9% |
| Unknown | 19 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 May 2017.
All research outputs
#3,647,251
of 22,973,051 outputs
Outputs from Drugs
#510
of 3,285 outputs
Outputs of similar age
#65,482
of 313,770 outputs
Outputs of similar age from Drugs
#6
of 43 outputs
Altmetric has tracked 22,973,051 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,285 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 313,770 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.